Ciara L. Freeman

2.4k total citations
87 papers, 934 citations indexed

About

Ciara L. Freeman is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Ciara L. Freeman has authored 87 papers receiving a total of 934 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 37 papers in Hematology and 33 papers in Pathology and Forensic Medicine. Recurrent topics in Ciara L. Freeman's work include Lymphoma Diagnosis and Treatment (32 papers), Multiple Myeloma Research and Treatments (29 papers) and CAR-T cell therapy research (26 papers). Ciara L. Freeman is often cited by papers focused on Lymphoma Diagnosis and Treatment (32 papers), Multiple Myeloma Research and Treatments (29 papers) and CAR-T cell therapy research (26 papers). Ciara L. Freeman collaborates with scholars based in United States, Canada and United Kingdom. Ciara L. Freeman's co-authors include Laurie H. Sehn, Ronan Swords, Francis J. Giles, Kerry J. Savage, Niamh Keane, Joseph M. Connors, Diego Villa, Alina S. Gerrie, David W. Scott and Graham W. Slack and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Ciara L. Freeman

74 papers receiving 922 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ciara L. Freeman United States	15	451	335	279	237	173	87	934
Gareth P. Gregory Australia	16	495 1.1×	421 1.3×	290 1.0×	184 0.8×	221 1.3×	74	956
Martha Glenn United States	15	275 0.6×	334 1.0×	206 0.7×	220 0.9×	250 1.4×	41	813
Mihaela Munteanu United States	14	538 1.2×	548 1.6×	195 0.7×	177 0.7×	339 2.0×	61	1.1k
Sarah M. Larson United States	14	343 0.8×	201 0.6×	180 0.6×	262 1.1×	200 1.2×	74	749
José María Sayagués Spain	23	292 0.6×	249 0.7×	367 1.3×	294 1.2×	231 1.3×	66	1.3k
Unn‐Merete Fagerli Norway	13	278 0.6×	201 0.6×	286 1.0×	261 1.1×	138 0.8×	33	744
Craig A. Portell United States	16	322 0.7×	409 1.2×	154 0.6×	117 0.5×	281 1.6×	65	765
Marie‐Christine Kyrtsonis Greece	18	392 0.9×	421 1.3×	376 1.3×	471 2.0×	497 2.9×	81	1.1k
Blanca Sánchez‐González Spain	20	304 0.7×	381 1.1×	721 2.6×	598 2.5×	196 1.1×	70	1.5k
Sergei Syrbu United States	16	399 0.9×	544 1.6×	173 0.6×	74 0.3×	259 1.5×	66	910

Countries citing papers authored by Ciara L. Freeman

Since Specialization

Citations

This map shows the geographic impact of Ciara L. Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ciara L. Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ciara L. Freeman more than expected).

Fields of papers citing papers by Ciara L. Freeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ciara L. Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ciara L. Freeman. The network helps show where Ciara L. Freeman may publish in the future.

Co-authorship network of co-authors of Ciara L. Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of Ciara L. Freeman. A scholar is included among the top collaborators of Ciara L. Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ciara L. Freeman. Ciara L. Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alduaij, Waleed, Laurie H. Sehn, Brett Collinge, et al.. (2025). Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC / BCL2 rearrangements, DLBCL morphology. Blood Advances. 10(2). 320–333.

Verbruggen, Stefaan W., Ciara L. Freeman, & Fiona E. Freeman. (2024). Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells’ Escape from the Bone Marrow Microenvironment. Cancers. 16(5). 889–889. 4 indexed citations

Kim, Soyoung, Binod Dhakal, Ayesha Aijaz, et al.. (2024). Outcomes of frail patients undergoing high‐dose chemotherapy and autologous stem cell transplantation for multiple myeloma. British Journal of Haematology. 205(6). 2370–2375.

Kalariya, Nilesh, Michelle A.T. Hildebrandt, Doris K. Hansen, et al.. (2024). Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Advances. 8(17). 4679–4688. 7 indexed citations

Letson, G. Douglas, Odion Binitie, Nicholas Figura, et al.. (2024). Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma. Critical Reviews in Oncology/Hematology. 201. 104429–104429.

Meads, Mark B., Xiaohong Zhao, David Noyes, et al.. (2024). De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression. Blood. 144(Supplement 1). 1906–1906.

Grajales‐Cruz, Ariel, Doris K. Hansen, Brandon Blue, et al.. (2024). P-027 Real World Experience of Standard of Care Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S56–S56. 1 indexed citations

Puglianini, Omar Castañeda, Doris K. Hansen, Brandon Blue, et al.. (2024). Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.. Journal of Clinical Oncology. 42(16_suppl). 7524–7524. 1 indexed citations

Freeman, Ciara L., Meghan Menges, Hien Liu, et al.. (2023). Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines. Blood. 142(Supplement 1). 1931–1931. 1 indexed citations

10.

Freeman, Ciara L., Meghan Menges, Jeffrey Edelman, et al.. (2023). Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clinical Cancer Research. 29(22). 4575–4585. 8 indexed citations

11.

Akhtar, Othman Salim, Biwei Cao, Xuefeng Wang, et al.. (2023). CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response. Blood Advances. 7(19). 5937–5940. 6 indexed citations

12.

Gerrie, Alina S., Kerry J. Savage, Diego Villa, et al.. (2023). Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis. Leukemia & lymphoma. 65(3). 346–352. 2 indexed citations

13.

Freeman, Ciara L., Xiaohong Zhao, Mark B. Meads, et al.. (2023). Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease. Blood. 142(Supplement 1). 3304–3304. 3 indexed citations

14.

Afrough, Aimaz, Hamza Hashmi, Doris K. Hansen, et al.. (2023). P-002 Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the U.S. myeloma CAR T consortium. Clinical Lymphoma Myeloma & Leukemia. 23. S33–S33. 1 indexed citations

15.

Villa, Diego, Ciara L. Freeman, Graham W. Slack, et al.. (2022). Clinicopathological characteristics and long‐term outcomes of plasmablastic lymphoma in British Columbia. British Journal of Haematology. 199(2). 230–238. 6 indexed citations

16.

John, Thomas, et al.. (2019). P1.01-136 Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: A Systematic Literature Review of Prevalence and Clinical Outcomes. Journal of Thoracic Oncology. 14(10). S416–S417. 1 indexed citations

17.

Freeman, Ciara L. & Laurie H. Sehn. (2018). A tale of two antibodies: obinutuzumab versus rituximab. British Journal of Haematology. 182(1). 29–45. 137 indexed citations

18.

Freeman, Ciara L., Sebastian Böttcher, Javier de la Serna, et al.. (2018). Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial. Blood. 132(Supplement 1). 4419–4419. 1 indexed citations

19.

Roberge, David, et al.. (2012). Poster — Thur Eve — 73: Prediction of risks of cardiac mortality and secondary cancers after radiotherapy for Hodgkin's lymphoma, non‐Hodgkin's lymphoma, and breast cancer. Medical Physics. 39(7Part4). 4639–4639.

20.

Swords, Ronan, Ciara L. Freeman, & Francis J. Giles. (2012). Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia. 26(10). 2176–2185. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact